Martin Vališ

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

Ivo N. van Schaik, Vera Bril, Nan van Geloven et al. · The Lancet Neurology · 2017 · 258 citations · Full text

Subcutaneous Immunoglobulin, Autoimmune Disease, Chronic Inflammatory +12

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch et al. · The Lancet Neurology · 2021 · 177 citations · Full text

Neurological Disorder, Phase 2B, Clinical Trials +7

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 173 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +5

Prolonged-release oxycodone–naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial

Claudia Trenkwalder, К. Ray Chaudhuri, Pablo Martínez‐Martín et al. · The Lancet Neurology · 2015 · 121 citations · Full text

Pain Disorders, Health Sciences, Severe Pain +12

Motion tracking and gait feature estimation for recognising Parkinson’s disease using MS Kinect

Ondřej Ťupa, Aleš Procházka, Oldřich Vyšata et al. · BioMedical Engineering OnLine · 2015 · 111 citations · Full text